29,773 Vericel Corporation $VCEL Shares Sold by Sterling Capital Management LLC

Sterling Capital Management LLC lessened its holdings in shares of Vericel Corporation (NASDAQ:VCEL) by 94.6% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,716 shares of the biotechnology company’s stock after selling 29,773 shares during the period. Sterling Capital Management LLC’s holdings in Vericel were worth $69,000 as of its most recent filing with the SEC.

Several other institutional investors also recently modified their holdings of VCEL. Inspire Investing LLC acquired a new stake in Vericel in the third quarter valued at $633,000. Kopp Family Office LLC lifted its holdings in Vericel by 0.6% during the 3rd quarter. Kopp Family Office LLC now owns 51,352 shares of the biotechnology company’s stock worth $2,061,000 after buying an additional 299 shares during the period. Juncture Wealth Strategies LLC lifted its holdings in Vericel by 19.9% during the 3rd quarter. Juncture Wealth Strategies LLC now owns 9,929 shares of the biotechnology company’s stock worth $399,000 after buying an additional 1,646 shares during the period. Tidal Investments LLC acquired a new position in Vericel during the 2nd quarter worth about $215,000. Finally, MCF Advisors LLC lifted its holdings in Vericel by 293.0% during the 2nd quarter. MCF Advisors LLC now owns 782 shares of the biotechnology company’s stock worth $35,000 after buying an additional 583 shares during the period.

Vericel Stock Up 1.4%

VCEL opened at $41.09 on Wednesday. Vericel Corporation has a twelve month low of $28.95 and a twelve month high of $49.32. The company has a fifty day moving average of $40.51 and a 200-day moving average of $38.70. The stock has a market cap of $2.10 billion, a PE ratio of 86.19 and a beta of 1.08.

Wall Street Analysts Forecast Growth

A number of research firms have commented on VCEL. Canaccord Genuity Group set a $60.00 price target on Vericel in a research report on Thursday, July 30th. Truist Financial lowered their price objective on Vericel from $58.00 to $52.00 and set a “buy” rating for the company in a research report on Wednesday, October 14th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Vericel in a research note on Thursday, October 29th. HC Wainwright reaffirmed a “buy” rating and issued a $70.00 price objective on shares of Vericel in a research note on Tuesday, July 28th. Finally, Wall Street Zen upgraded Vericel from a “hold” rating to a “buy” rating in a report on Saturday, July 18th. Four investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $57.20.

Vericel Company Profile

Vericel Corporation is a commercial-stage biopharmaceutical company focused on developing and marketing advanced cell therapies and regenerative medicine products. The company serves orthopedic and burn-care markets, with an emphasis on treatments that use a patient’s own cells or biologic materials to support tissue repair and healing.

Vericel’s primary orthopedic product is MACI, an autologous cultured chondrocyte implant used to repair symptomatic cartilage defects of the knee in adults.